Practice Gaps — Where Menopause Care Falls Short

These are documented gaps between what the evidence supports and what patients actually receive. Each gap is sourced to specific research.

1. GSM Undertreatment at Scale

The gap: 71.22% of 2,867,232 diagnosed cases of postmenopausal atrophic vaginitis received no recorded treatment (TriNetX 2004-2024). Among those treated, topical estrogen dominated (88.64%), with prasterone (0.50%) and ospemifene (0.21%) rarely prescribed.

Population affected: Postmenopausal women with diagnosed atrophic vaginitis / GSM-related diagnosis across the US healthcare system.

System-level cause: Not established by this dataset — may reflect provider familiarity, patient preference, contraindication, access barriers, OTC self-management, or care outside the EHR network.

Source: PMID 41496540 | Full context: Genitourinary Health section

2. Provider Non-Initiation of Menopause Conversations

The gap: Across multiple studied populations, healthcare providers essentially never proactively raise menopause. Among 334 African American women, 0% reported their provider proactively asking about menopause; 76% of those who did not seek care said their provider did not seem concerned; 63% were waiting for their provider to bring it up.

Population affected: African American women (directly measured), with consistent patterns reported in UK immigrant Muslim, Nigerian, Omani, and Australian populations.

System-level cause: Likely contributors described in the source literature include clinician training gaps, competing visit priorities, cultural silence, and lack of structured menopause-care protocols.

Sources: PMID 41550478, 40025693, 41656159, 41786907, 41145319 | Full context: What to Watch For and Special Populations sections

3. Breast Cancer Survivor Symptom Burden and Treatment Gap

The gap: 90% of breast cancer survivors 6 years post-diagnosis reported VMS or sleep disturbance, 75% vaginal dryness, 62% mood swings, 59% sexual difficulties. Less than one-third were offered treatment. Less than half of those who received treatment found it effective.

Population affected: Breast cancer survivors, particularly those on adjuvant endocrine therapy.

System-level cause: Likely contributors described in the source literature include provider uncertainty about hormonal treatment safety after cancer, limited evidence-based non-hormonal alternatives, and risk-avoidant practice patterns around hormonal intervention.

Source: PMID 38458217 | Full context: Breast Cancer & HRT section

4. AUB Workup Disparities in US Emergency Departments

The gap: In 7.9 million US ED visits for non-pregnancy abnormal uterine bleeding (2014-2021), Black patients had less than half the odds of receiving ultrasound or referral compared to White patients (composite aOR 0.46). Perimenopausal-age women (46-55) had significantly lower referral odds than younger women (aOR 0.31). Rural patients faced the steepest disparity (composite aOR 0.13).

Population affected: Black women, perimenopausal-age women, and rural women presenting with AUB in US emergency departments.

System-level cause: Structural process-of-care inequity — the study measured what providers did, not patient behavior. Providers may normalize perimenopausal-age AUB.

Source: PMID 40897603 | Full context: What to Watch For section

5. Workplace Support Gap

The gap: Among 1,642 US employees experiencing menopause, only 9% received any workplace support despite 83% having menopause experience and 50% feeling comfortable discussing it with colleagues. 47% reported difficulty concentrating, 41% increased stress. Estimated annual cost: $1.8 billion in lost US workdays.

Population affected: Working women in the US during the menopausal transition.

System-level cause: Likely contributors described in the source literature include absence of workplace menopause policies, ageism fears preventing disclosure, and lack of employer awareness.

Source: PMID 40591541 | Full context: Understanding Your Condition section

6. LMIC Evidence and Access Gap

The gap: Across 41 low- and middle-income countries, only 4% of menopause studies were nationally representative, only 17.5% used STRAW+10/WHO criteria, and 85% were cross-sectional. National-level age-at-menopause data are lacking. HRT formulary availability ranges from 3/20 medicines (Nepal) to 18/20 (Brazil), and affordability diverges dramatically — one combined HRT product in Nigeria costs 260 minimum-wage days for a 2-month supply.

Population affected: Women in LMICs, rural women, and expatriate women in settings with limited formulary access.

System-level cause: Methodological evidence-quality gap, limited formulary availability, extreme affordability barriers, guidelines designed for resource-rich settings.

Sources: PMID 40536363, 42036422 | Full context: Special Populations section

7. Systemic HT Prescribing in Breast Cancer Survivors

The gap: In a real-world study of 618 breast cancer survivors on endocrine therapy, 15.2% of VMS prescriptions were systemic hormone therapy — notable because systemic HT is generally considered higher-risk in many BCS contexts. About one-third (33.1%) of those with moderate-to-severe VMS had no current prescribed treatment. The dataset did not distinguish ER status or explain prescribing rationale.

Population affected: Breast cancer survivors on endocrine therapy across US and 5 European countries.

System-level cause: Unclear — may reflect clinician judgment, patient-driven decisions, or inadequate non-hormonal alternatives. Pre-NK-antagonist-era data.

Source: PMID 39059108 | Full context: Vasomotor Symptoms and Breast Cancer & HRT sections

8. Mental Health Screening Gap

The gap: No standardized mental health guidelines for menopausal women exist. Most validated screening scales were developed in English-speaking populations. Women with consistently high pre-FMP depressive symptoms (12.4% of the SWAN cohort) carry an OR of 6.88 for postmenopausal depression — yet routine screening before the menopausal transition is not standard practice.

Population affected: Women entering perimenopause with prior depression history or elevated depressive symptoms, and women in non-English-speaking populations.

System-level cause: Likely contributors described in the source literature include lack of menopause-specific mental health guidelines, cross-cultural tool validation gaps, and clinical inertia around pre-transition screening.

Sources: PMID 41902367, 41476384, 35796553 | Full context: Evidence Landscape, What to Watch For, and Mood Sleep & Cognition sections

9. Dismissive Care as Global Pattern

The gap: Across geographically and culturally distinct populations, women consistently report being dismissed by healthcare providers regarding menopause concerns. UK immigrant Muslim women reported GP refusal of HRT and dismissive encounters. Nigerian women described "limited anticipatory information" and "inadequate clinician training." Omani women found HRT available only as oral tablets (no patches or gels). Australian women described being told to "just put up with it."

Population affected: Women across high-income and low-middle-income countries — not a region-specific phenomenon.

System-level cause: Likely contributors described across the source literature include clinician training gaps, cultural silence, limited formulary availability, and systemic deprioritization of menopause care.

Sources: PMID 40025693, 41656159, 41786907, 41145319 | Full context: Special Populations section